En undersøgelse af sikkerheden og effekten af Tapinarof-creme, 1%, hos deltagere i alderen 3 måneder til under 24 måneder med atopisk eksem (Adoring)
Et randomiseret, dobbeltblindt, køretøjskontrolleret (periode 1) og åben-etiket (periode 2) fase 3-studie til undersøgelse af sikkerhed og effekt af Tapinarof-creme, 1 % hos børnedeltagere i alderen 3 måneder til < 24 måneder med atopisk eksem
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2J 7E1
- Dermatology Research Institute
-
Red Deer, Alberta, Canada, T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington, Ontario, Canada, L7L 6W6
- Halton Pediatric Allergy
-
Hamilton, Ontario, Canada, L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls, Ontario, Canada, L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon, Saskatchewan, Canada, S7K 2C1
- Skinsense Medical Research
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, Forenede Stater, 72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles, California, Forenede Stater, 90045
- Dermatology Research Associates
-
Sacramento, California, Forenede Stater, 95815
- Integrative Skin Science and Research
-
San Diego, California, Forenede Stater, 92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks, California, Forenede Stater, 91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock, Colorado, Forenede Stater, 80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33486
- Skin Care Research, LLC.
-
Jacksonville, Florida, Forenede Stater, 32256
- APEX Clinical Trials
-
Wellington, Florida, Forenede Stater, 33449
- TruDerm Research
-
-
Georgia
-
Cumming, Georgia, Forenede Stater, 30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian, Idaho, Forenede Stater, 83646
- Ada West Research
-
-
Illinois
-
Skokie, Illinois, Forenede Stater, 60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, Forenede Stater, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green, Kentucky, Forenede Stater, 42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville, Maryland, Forenede Stater, 20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills, Michigan, Forenede Stater, 48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton, Minnesota, Forenede Stater, 55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland, Mississippi, Forenede Stater, 39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph, Missouri, Forenede Stater, 64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens, New York, Forenede Stater, 11415
- Forest Hills Dermatology Group
-
New York, New York, Forenede Stater, 10012
- Bobby Buka MD, PC
-
The Bronx, New York, Forenede Stater, 10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn, Ohio, Forenede Stater, 45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
North Charleston, South Carolina, Forenede Stater, 29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire, Texas, Forenede Stater, 77401
- The University of Texas Health Science Center at Houston
-
Dallas, Texas, Forenede Stater, 75230
- Dermatology Treatment and Research Center
-
Southlake, Texas, Forenede Stater, 76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99202
- Dermatology Specialists of Spokane
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Andre navne:
|
|
Placebo komparator: Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsramme: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsramme: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Lead Late-Stage Clinical Development, Organon and Co
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- OG0505-3104
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .